At #ESMO26, results from the Phase 2 DOVACC trial showed adding the UV1 cancer vaccine to olaparib +/- durvalumab did not significantly improve PFS in BRCA wild-type recurrent ovarian cancer🧬
@myesmo.bsky.social #ESMO2026
Full article: https://bit.ly/3UaDJVt
At #ESMO26, results from the Phase 2 DOVACC trial showed adding the UV1 cancer vaccine to olaparib +/- durvalumab did not significantly improve PFS in BRCA wild-type recurrent ovarian cancer🧬 @myesmo.bsky.social #ESMO2026 Full article: https://bit.ly/3UaDJVt
0 vue
Publié le 23/10/2026 20:07
0:10
At #ESMO26, results from the Phase 2 DOVACC trial showed adding the UV1 cancer vaccine to olaparib +/- durvalumab did not significantly improve PFS in BRCA wild-type recurrent ovarian cancer🧬
@myesmo.bsky.social #ESMO2026
Full article: https://bit.ly/3UaDJVt
0 commentaire
?